A second shot at PARP1 from Eikon
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
Bristol seeks another celmod use
Golcadomide will begin a new pivotal trial in follicular lymphoma.
Head and neck cancer is next for evorpacept
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
Vor looks to answer the Car-T question
Can the company add a Car-T string to its stem cell transplant bow?
The first clinical-stage dual-payload conjugate
Chengdu Kanghong's KH815 enters human testing this month.
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
The month ahead: April’s upcoming events
AACR approaches, along with ASCO abstract titles.
